📅 PUBMED DAILY TRIAGE — 2026-05-29 (Friday)
Window: 2026-05-28T09:00:00Z → 2026-05-29T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed (candidates evaluated): ~95 | Classified: 18 High priority: 4 | Standard: 9 | Low/archive: 5 | Unsolicited finds: 2 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Novel Therapeutics (Immunotherapy / CAR-T / Targeted Therapy)
TR-2026-05-29-001 / PMID 42207176 · Intrathecal Allogeneic B7-H3-targeted CAR γδ T Cells for Leptomeningeal Metastasis · 8/10 🟠 NOVEL_TREATMENT
Phase 1 trial (n=3) of intrathecal off-the-shelf B7-H3-CAR γδ T cells in LM from solid tumors: SD in all 3 patients at day 30, 1 CSF cytology conversion, no grade ≥4 TRAEs, with IFN-γ-associated immune remodeling in CSF. Clin Cancer Res. First proof-of-concept for this allogeneic route/target/cell type combination.
TR-2026-05-29-004 / PMID 42207343 · Predictors of pCR in early-stage TNBC with neoadjuvant chemo-immunotherapy · 7/10 🟠 NOVEL_TREATMENT
Multi-institution retrospective cohort (n=374), pCR rate 61.2% with KEYNOTE-522 regimen in diverse real-world population (29% non-White, 48% BMI ≥30); diabetes independently predicted lower pCR (p=0.03 multivariate) — novel metabolic resistance hypothesis. Breast Cancer Res Treat.
Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)
TR-2026-05-29-003 / PMID 42207402 · Circulating Tumor High Risk HPV DNA as HPV-Specific Test in OPSCC · 7/10 🔴 EARLY_CANCER_DETECTION
ctHPV DNA (NavDx assay, 236 patients, Mayo Clinic): 100% specificity, 100% PPV — a positive result may eliminate need for tissue HPV testing in high-suspicion OPSCC. Negative results still require tissue confirmation (83% false-negative rate). Head Neck Pathol.
Sentinel / Diagnostics (Unsolicited)
TR-2026-05-29-002 / PMID 42207513 · Validation of a 2-Gene Blood Test for Kawasaki Disease in Febrile Children · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE (unsolicited find)
Multicenter validation (n=541, Taiwan+Shanghai): 2-gene qPCR (IFI27+MCEMP1), AUC 0.91, 94% sensitivity, 82% specificity for Kawasaki disease vs. febrile illnesses. First objective molecular test approaching KD clinical utility; implemented as lab-developed test. JAMA Netw Open.
🟢⚪ STANDARD (5–7) — Top by Topic
Hematologic Malignancies
- TR-2026-05-29-007 / PMID 42207484 · vanA VRE colonization associated with inferior OS in AML induction · 6/10 — Retrospective cohort (n=192); vanA phenotype (18.2% of VRE-colonized AML) independently linked to worse OS vs vanB. Infection journal.
- TR-2026-05-29-008 / PMID 42207485 · Clinical implications of MRD monitoring in multiple myeloma (review) · 5/10 — MRD-adapted therapy paradigm review; NGS/NGF methods; Int J Hematol.
- TR-2026-05-29-012 / PMID 42185479 · Copper depletion boosts CNS leukemia therapy (preclinical) · 5/10 — Nat Cancer; non-human cap; deferred from 2026-05-28 run; promising mechanism.
CBC/ML in Hematology
- No high-priority finds today (0 results; sparse streak day 2)
Early Cancer Detection / Liquid Biopsy
- TR-2026-05-29-013 / PMID 42205214 · cfDNA methylation panel for lung cancer detection · 5/10 — Observational; Indian J Clin Biochem; PMC embargoed 2027.
AI/ML in Clinical Diagnostics
- TR-2026-05-29-006 / PMID 42206490 · Evidence Aggregator: AI reasoning for rare disease diagnostics · 7/10 — Microsoft/Broad tool; 92% recall, 34% time reduction in user study; Genet Med.
Precision Oncology / Genomics
- TR-2026-05-29-006 / PMID 42206490 (cross-listed above)
- TR-2026-05-29-008 / PMID 42207485 (cross-listed above)
Novel Therapeutics — Additional
- (PALADIN trial design at 4/10 LOW — see below)
Cardiovascular-Metabolic (GLP-1 / SGLT2)
- TR-2026-05-29-009 / PMID 42207473 · GLP-1 RA thyroid cancer AEs in European pharmacovigilance database · 5/10 — Disproportionality analysis; Pharmacol Rep.
- TR-2026-05-29-010 / PMID 42207410 · Differential biliary AE signals across GLP-1 RAs: FAERS analysis · 5/10 — Agent-specific biliary risk signals; Dig Dis Sci.
Aging / Longevity / Population Health
- TR-2026-05-29-011 / PMID 42205455 · Co-occurring health behaviors and mental health in aging US population · 5/10 — Large ACS cohort; behavior clustering; Front Public Health (PMC open).
Rare Diseases
- TR-2026-05-29-006 / PMID 42206490 (cross-listed above — AI tool for rare disease diagnostics)
Sentinel (Unsolicited Finds — STANDARD)
- TR-2026-05-29-005 / PMID 42207508 · Longitudinal risk for suicidal self-directed violence in veterans with cancer · 7/10 🟡 UNDERSERVED — National VA cohort (n=292,271, 2014-2023); SSDV rate 203/100k person-years; high-risk subgroups incl. younger, Asian veterans, thyroid cancer. JAMA Oncol.
💡 UNSOLICITED FINDS
| Record | PMID | Title | Score | Note |
|---|---|---|---|---|
| TR-2026-05-29-002 | 42207513 | 2-Gene Blood Test for Kawasaki Disease (JAMA Netw Open) | 8/10 | Elevated to HIGH — NEAR_TERM_IMPLEMENTABLE; rare disease/diagnostics crossover |
| TR-2026-05-29-005 | 42207508 | Veterans with Cancer + Suicide Risk Longitudinal (JAMA Oncol) | 7/10 | STANDARD UNDERSERVED_POPULATION; public health high-signal find |
📊 TODAY'S BREAKDOWN
By research category:
- Treatment Innovation: 3 (001, 004, 016)
- Diagnostics: 5 (002, 003, 006, 007, 014)
- Early Detection: 2 (003, 013)
- Drug Development: 3 (009, 010, 012)
- Public Health: 3 (005, 011, 015)
- Genomics/Precision Medicine: 2 (008, 018)
By evidence maturity:
- Exploratory: 11
- Validated: 5 (002, 003, 004, 006, 008)
- Potentially Practice-Changing: 0
By watchlist topic (reviewed / classified HIGH / highest score):
| Topic | Reviewed | HIGH | Highest Score |
|---|---|---|---|
| Hematologic Malignancies | 10 | 0 | 6/10 (42207484) |
| CBC/ML in Hematology | 0 | 0 | 0 |
| Early Cancer Detection (ctDNA/LiqBx) | 8 | 1 | 7/10 (42207402) |
| AI/ML Diagnostics | 10 | 0 | 7/10 (42206490) |
| Precision Oncology | 10 | 0 | 7/10 (42206490) |
| Novel Therapeutics | 10 | 2 | 8/10 (42207176) |
| Cardiovascular-Metabolic | 10 | 0 | 5/10 |
| Aging/Longevity | 9 | 0 | 5/10 (42205455) |
| Rare Diseases | 10 | 0 | 7/10 (42206490) |
| Sentinel | 10 | 1 | 8/10 (42207513) |
By source type: peer_reviewed: 18 | preprint: 0
Topics with zero 8+ articles this run:
- Hematologic Malignancies (best: 6/10 VRE+AML — no treatment innovation today)
- CBC/ML in Hematology (zero results — 2-day sparse streak)
- Early Cancer Detection (best: 7/10 via flag-elevated ctHPV DNA)
- AI/ML Diagnostics (best: 7/10 EvAgg)
- Precision Oncology (best: 7/10 EvAgg)
- Cardiovascular-Metabolic (best: 5/10)
- Aging/Longevity (best: 5/10)
- Rare Diseases (best: 7/10 EvAgg)
🔧 RUN NOTES
Deferred PMID resolution: PMID 42185479 (Nat Cancer, copper + CNS leukemia) re-reviewed as deferred from 2026-05-28. Confirmed preclinical (mouse/cell); non-human cap 5/10 maintained. Scored STANDARD / PROMISING_PRELIMINARY. No further deferral needed.
CBC/ML topic: Zero results for second consecutive day. Streak flagged. No run expansion triggered (total across all topics far >5 relevant records).
Aging/longevity query: humans[MeSH] filter working effectively (9 results, all human-relevant). Top hits (42205455, 42204869, 42204867) all legitimate aging/aging-adjacent human studies — no non-human contamination this run. Filter is effective.
Window expansion: NOT triggered. 18 qualifying records across all topics.
Novel therapeutics strongest topic today: 2 HIGH articles — intrathecal CAR γδ T cells (novel mechanism, Phase 1) and real-world TNBC neoadjuvant immunotherapy predictors.
PALADIN trial design (42205796): Phase II design paper only; no efficacy results. Scored LOW 4/10. Will monitor for results.
Menin inhibitor pseudoprogression note (42207547): Title-only record in Blood (likely brief communication). Clinically relevant concept (menin inhibitors now in AML practice) but cannot score above 3 without abstract. Worth monitoring for subsequent full paper.
Rolling 7-day sparse streak tracker:
- CBC/ML: 2 consecutive days with 0 results (May 28-29)
- All other topics: producing results